293 related articles for article (PubMed ID: 33626547)
1. Complete Transurethral Resection before Radical Cystectomy May Improve Oncological Outcomes.
Graffeille V; Verhoest G; Gryn A; Kammerer-Jacquet SF; Alimi Q; Beauval JB; Beuzit L; Pradère B; Thoulouzan M; Khene ZE; Guille F; Rioux-Leclercq N; Mathieu R; Gamé X; Bensalah K; Soulié M; Roumiguié M; Peyronnet B
Urol Int; 2022; 106(2):122-129. PubMed ID: 33626547
[TBL] [Abstract][Full Text] [Related]
2. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
Ghandour RA; Kusin S; Wong D; Meng X; Singla N; Freifeld Y; Bagrodia A; Margulis V; Sagalowsky A; Lotan Y; Woldu SL
Urol Oncol; 2020 Sep; 38(9):736.e11-736.e18. PubMed ID: 32684514
[TBL] [Abstract][Full Text] [Related]
3. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
Zheng Y; Ye Y; Chen J; Wei Z; Liu Z; Yu K; Zhang X
Int J Surg; 2022 Jul; 103():106693. PubMed ID: 35690361
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.
Rehme C; Fritsch B; Thomas L; Istin S; Burchert C; Hummel B; Baleanu-Curaj B; Reis H; Szarvas T; Ruebben H; Hadaschik B; Niedworok C
Int Urol Nephrol; 2022 Jan; 54(1):71-79. PubMed ID: 34817753
[TBL] [Abstract][Full Text] [Related]
6. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
[TBL] [Abstract][Full Text] [Related]
7. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
8. The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy.
Zamboni S; Moschini M; Gallina A; Colombo R; Montorsi F; Briganti A; Salonia A; Antonelli A; Simeone C; Belotti S; Cristinelli L; Mattei A; Baumeister P
World J Urol; 2019 Dec; 37(12):2707-2714. PubMed ID: 30911811
[TBL] [Abstract][Full Text] [Related]
9. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
10. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
[TBL] [Abstract][Full Text] [Related]
11. Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer.
Baird B; Bilgili A; Anderson A; Carames G; Pathak RA; Ball CT; Pak R; Zganjar A; Young PR; Lyon TD
Int Braz J Urol; 2023; 49(4):479-489. PubMed ID: 37267613
[TBL] [Abstract][Full Text] [Related]
12. Impact of transurethral resection of bladder tumor: analysis of cystectomy specimens to evaluate for residual tumor.
Lee SE; Jeong IG; Ku JH; Kwak C; Lee E; Jeong JS
Urology; 2004 May; 63(5):873-7; discussion 877. PubMed ID: 15134968
[TBL] [Abstract][Full Text] [Related]
13. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
14. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Yabana T
Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
[TBL] [Abstract][Full Text] [Related]
15. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
Solsona E; Climent MA; Iborra I; Collado A; Rubio J; Ricós JV; Casanova J; Calatrava A; Monrós JL
Eur Urol; 2009 Apr; 55(4):911-9. PubMed ID: 18722046
[TBL] [Abstract][Full Text] [Related]
16. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
[TBL] [Abstract][Full Text] [Related]
17. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e1-684.e8. PubMed ID: 32201059
[TBL] [Abstract][Full Text] [Related]
19. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]